Search 

Selcia, now part of Eurofins, is a global leader in 14C custom radiolabelling, stable isotope labelling and analytical services. With many years of experience our team of expert synthetic radiochemists can prepare radiolabelled molecules of almost any complexity for use in regulatory studies by the life sciences and chemical industries to understand: preclinical and clinical drug metabolism, human mass balance (GMP 14C Radiolabelled API), dermal penetration, tissue distribution and environmental fate. Selcia also offers GLP NMR and analytical problem solving services to support regulatory submissions, as well as the profiling and synthesis of metabolites and process impurities.  www.selcia.com 

• 14C Custom Radiolabelling for pre-clinical studies (ADME, Dermal Penetration, E-fate)  
• GMP Radiolabelled API for Clinical Trials , 14C-API for hAME and mass balance  
• Stable Labelling  (13C, 2H, 15N) Internal Standards, Metabolites and Impurities  
• GLP Analysis Certification and Problem Solving including GLP NMR 

Radiolabelling to support Life Sciences: • Metabolism • Distribution • Mass Balance • Micro-dosing • Environmental fate • Dermal Penetration 

Evotec has been a leader in drug discovery and development for over 30 years, offering end-to-end solutions from target identification to clinical trials. Their innovative approach leverages deep disease understanding, cutting-edge technologies, and tailored solutions, supporting collaborations through standalone services, integrated programs, or strategic partnerships to create impactful medicines.

HistologiX is a leading GLP/GCP compliant CRO supporting tissue based evaluation of your biomarkers; they help you visualise and understand what your drug or device is doing to your key biomarkers at the cellular and tissue level. Their experienced scientific team work as an extension of your in-house team and provide specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridisation (ISH) using RNAScope, digital pathology and image analysis services.

hVIVO plc (ticker: HVO) is a fast growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The Group provides end-to-end early clinical development services to its large, established and growing repeat client base, which includes four of the top 10 largest global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 11 human challenge models, with a number of new models under development, to test a broad range of infectious and respiratory disease products. The Group has world class challenge agent manufacturing capabilities, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group also offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge trials in London - its new state-of-the-art facilities in Canary Wharf opened in 2024 and is the world's largest commercial human challenge trial unit, with highly specialised on-site virology and immunology laboratories, and an outpatient unit. To recruit volunteers / patients for its studies, the Group leverages its unique clinical trial recruitment capability via its FluCamp volunteer screening facilities in London and Manchester.

ichorbio is a manufacturer of bulk in vivo antibodies and research biosimilars based in Oxford, United Kingdom.

At ichorbio, their vision is to develop the highest quality reagents to advance scientific research and progress. They believe that the excellence of our products directly impacts the meaningfulness of research outcomes.

As a boutique reagent manufacturer, their target customers are scientists seeking reliable antibodies and other research tools. They aim to provide these products at fair prices - keeping our focus on customers, not shareholders.

Thier best selling in vivo products include RMP1-14, 10F.9G2 and 2.43. Their best selling research biosimilars include mosunetuzumab, odronextamab and aflibercept. Their best selling isotype controls include Rat IgG2a isotype control, Rat IgG2b isotype control, Human IgG1 isotype control and Human IgG4 S228P isotype control. 

IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.

Intract Pharma Limited is an oral drug delivery licensing and product development company offering a range of proprietary formulation technologies to deliver novel and optimised therapeutics targeted to patient needs. The company is a spin-out of University College London, and is centred around over 15 years of research and innovation from the laboratory of Professor Abdul Basit. Intract's range of formulation technologies includes Phloral™ for colon targeted delivery, and ProRelease™, a versatile microparticulate delivery system.

Isogenica is at the forefront of synthetic biology, pursuing a mission to provide the fastest, most efficient engine for therapeutic antibody discovery. Isogenica is developing LlamdA™ (single domain VHH) and Alexandria™ (human Fab) therapeutic antibodies based on its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.

Our team combines drug discovery specialists with physicists, chemists and computer scientists committed to use cutting-edge technologies to make a difference to people’s lives.

Kuano's approach is to combine state-of-the-art simulation and AI to add quantum detail to structure based drug discovery. Our unique fusion of drug hunting and technology expertise allows us to illuminate new areas of chemical space enabling the design of next generation medicines.